Ovid Therapeutics Is A Biopharmaceutical Company Based In New York Cityfocused On Developing Medicines For Patients With Neurological Disordersparticularly Rare And Epileptic Conditionsthe Company Aims To Enhance The Lives Of Individuals And Families Affected By These Diseases Through Innovative Science And Targeted Therapies Ovid Therapeutics Specializes In Small Molecule Therapieswith A Pipeline That Includes Several Compounds In Various Stages Of Developmentnotable Projects Include Ov101 For Angelman Syndromeov329 For Epilepsyand Ov4071 For Parkinson S Disease And Lewy Body Dementiathe Company Is Committed To Engaging With Communities Impacted By These Conditionsincorporating Their Insights Into The Research And Development Process With A Strong Emphasis On Research And Developmentovid Therapeutics Invested $35 7 Million In 2023The Company Collaborates With Leading Institutions And Partners To Advance Its Therapeutic Pipelineovid Therapeutics Is Publicly Traded On Nasdaq Under The Ticker Symbol Ovid
No conferences found for this company.
| Company Name | Ovid Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
